Search This Blog

Tuesday, April 7, 2026

FDA OKs Artivion-Endospan's NEXUS Aortic Arch System, triggers Artivion option to acquire Endospan

 

FDA approves Artivion and Endospan's NEXUS Aortic Arch System, triggering Artivion's 90-day option to acquire Endospan

  • Artivion arranged a $150 million delayed-draw term loan facility to finance the potential Endospan acquisition.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)